Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Foghorn Therapeutics (FHTX) Profit After Tax (2020 - 2025)

Foghorn Therapeutics (FHTX) has 6 years of Profit After Tax data on record, last reported at -$17.9 million in Q2 2025.

  • For Q2 2025, Profit After Tax rose 21.95% year-over-year to -$17.9 million; the TTM value through Jun 2025 reached -$75.4 million, up 12.78%, while the annual FY2025 figure was -$74.3 million, 14.22% up from the prior year.
  • Profit After Tax reached -$17.9 million in Q2 2025 per FHTX's latest filing, up from -$18.8 million in the prior quarter.
  • Across five years, Profit After Tax topped out at -$14.3 million in Q3 2023 and bottomed at -$30.5 million in Q1 2023.
  • Average Profit After Tax over 5 years is -$24.0 million, with a median of -$24.6 million recorded in 2023.
  • Peak YoY movement for Profit After Tax: plummeted 64.75% in 2021, then surged 44.44% in 2023.
  • A 5-year view of Profit After Tax shows it stood at -$29.1 million in 2021, then increased by 0.82% to -$28.9 million in 2022, then rose by 16.54% to -$24.1 million in 2023, then grew by 19.18% to -$19.5 million in 2024, then rose by 7.94% to -$17.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Profit After Tax were -$17.9 million in Q2 2025, -$18.8 million in Q1 2025, and -$19.5 million in Q4 2024.